泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01011 泰凌医药

未开盘 09-17 16:00:00

0.360

+0.000

0.00%

最高0.420	最低0.420	成交量3.00万
今开0.420	昨收0.360	日振幅0.00%
总市值6.47亿	流通市值6.47亿	总股本17.97亿
成交额1.26万	换手率0.00%	流通股本17.97亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01011","market":"HK","secType":"STK","nameCN":"泰凌医药","latestPrice":0.36,"timestamp":1789632000005,"preClose":0.36,"halted":0,"volume":30000,"delay":0,"changeRate":0,"floatShares":1797000000,"shares":1797000000,"eps":-0.04221,"marketStatus":"未开盘","change":0,"latestTime":"09-17 16:00:00","open":0.42,"high":0.42,"low":0.42,"amount":12600,"amplitude":0,"askPrice":0.45,"askSize":10000,"bidPrice":0.355,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.018,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":0,"adr":0,"listingDate":1303228800000,"exchange":"SEHK","adjPreClose":0.36,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"volumeRatio":1.3568521031207599,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01011","defaultTab":"news","newsList":[{"id":"2667666940","title":"泰凌医药(01011)委任国卫为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667666940?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:43","pubTimestamp":1789389807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，经考虑本公司审核委员会的推荐建议，董事会已议决委任国卫会计师事务所有限公司(国卫)为本公司新核数师，以填补大华马施云退任后的临时空缺，自股东于股东特别大会上批准之日起生效，且其任期将直至本公司下一届股东周年大会结束为止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104941084","title":"泰凌医药(01011)拟改聘国卫会计师事务所　估计年度审计费约89.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104941084","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104941084?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:42","pubTimestamp":1789389726,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司9月14日公告，董事会根据审计委员会建议，议决委任国卫会计师事务所有限公司为公司新核数师，自股东特别大会通过普通决议案之日起生效，任期至下一届股东周年大会结束。该项委任尚待股东特别大会批准。此前，8月28日召开的股东特别大会就委任中正天恒会计师有限公司为核数师的决议案因赞成票不足50%未获通过。董事会于9月10日至11日正式议决委任国卫。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339840","title":"泰凌医药(01011.HK)发行 8.476亿股认购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664339840?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:13","pubTimestamp":1788520431,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143676995","title":"泰凌医药：9月4日配发及发行847,565,892股新股，总金额约3.09亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143676995","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143676995?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:11","pubTimestamp":1788520313,"startTime":"0","endTime":"0","summary":"泰凌医药于2026年9月4日发布公告，公司根据于2026年8月28日召开的股东特别大会所批准的特定授权，向包括Golden Base Investment Limited、Annie Investment Co., Limited、吴静杰、吴静美、吴铁、黄剑山及杭州艾斯生命科技有限公司在内共7名认购方，配发及发行847,565,892股认购股份。本次发行股份占此前948,997,694股已发行股本的约89.31%。本次新股的发行价为每股0.365港元，发行总金额约3.09亿港元。公告由执行董事吴铁签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰凌医药：9月4日配发及发行847,565,892股新股，总金额约3.09亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138301308","title":"泰凌医药(01011)完成8.48亿股贷款资本化认购　总股本扩至17.97亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138301308","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138301308?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:01","pubTimestamp":1788519708,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年9月4日公告，旗下根据特别授权进行的贷款资本化认购事项已完成。公司确认，《认购协议》所载全部先决条件已获达成，认购股份亦于同日正式配发及发行。此次公司按每股0.365港元的认购价，向多名认购人合共发行847,565,892股新股，占经扩大后已发行股本约47.18%。发行完成前，公司已发行股份为948,997,694股；完成后增至1,796,563,586股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137574049","title":"泰凌医药更新8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137574049","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137574049?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:30","pubTimestamp":1788496241,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年9月4日发布截至2026年8月31日的月度股份变动月报表。公告显示，公司在报告期内并无新增发行、购回或注销股份，整体股本保持稳定。根据月报，泰凌医药本月底普通股已发行股份总数为948,997,694股，与上月底一致；优先股数量亦无变化，均保持在32,500,000股。公告显示，8月份公司无额外发行或库藏股的变动，已发行股份及股本规模与上月底保持一致。公司表示将继续严格依照监管规定履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663304006","title":"泰凌医药(01011)：王志强获委任为公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2663304006","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663304006?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:26","pubTimestamp":1788182784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，李怡芳女士已辞任公司的公司秘书、香港联合交易所有限公司证券上市规则第3.05条项下公司的授权代表及上市规则第19.05(2)条及公司条例(香港法例第622章)第16部项下代表公司于香港接收法律程序文件及通知的代理人(法律程序代理人)，自2026年8月31日起生效。王志强先生已获委任为公司的公司秘书、授权代表及法律程序代理人，自2026年8月31日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189733199","title":"泰凌医药（01011）公告人事变动：公司秘书及授权代表8月31日交接","url":"https://stock-news.laohu8.com/highlight/detail?id=1189733199","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189733199?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:21","pubTimestamp":1788182471,"startTime":"0","endTime":"0","summary":"泰凌医药8月31日在港交所发布公告称，公司董事会已收到李怡芳女士的辞任，李怡芳将自2026年8月31日起不再担任公司秘书、根据上市规则第3.05条的授权代表，以及根据上市规则第19.05条及香港《公司条例》第16部的法律程序代理人。李怡芳确认与董事会无意见分歧，亦无需提请股东及联交所特别关注的事项。董事会感谢李怡芳在任期间的贡献，并对王志强的加入表示欢迎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663702584","title":"泰凌医药(01011.HK)转仓市值总计2244.08万港元 占比5.91% 从新永安国际证券转出5600万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663702584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663702584?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:59","pubTimestamp":1788137995,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181584047","title":"泰凌医药(01011)股东特别大会表决结果：认购协议议案获通过，会计师事务所委任议案未获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1181584047","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181584047?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:02","pubTimestamp":1787929360,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司2026年8月28日举行股东特别大会并公布表决结果。大会就两项普通决议进行投票，结果如下：。根据股东特别大会公告，需回避投票的股东共持有505,651,342股，因此对此议案有权投票的股份总数为443,346,352股。由于少于50%的有效投票赞成，该议案未获通过。146,520,146股因无效投票未计入第一项议案的表决结果。公司表示，鉴于第二项议案未获通过，将继续物色合适的核数师并于适当时候召开新的股东特别大会审议相关委任事宜。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103953337","title":"泰凌医药（01011）发布2026财年中期业绩：收入增至2,366.5万元 亏损小幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1103953337","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103953337?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:26","pubTimestamp":1787235964,"startTime":"0","endTime":"0","summary":"2026年8月20日，中国泰凌医药集团有限公司公布截至2026年6月30日止六个月未经审核中期业绩。– 收入为2,366.5万元，同比增加97.2%。– 期内亏损1,653.7万元，较上年同期的1,690.6万元减少36.9万元。– 基本及摊薄每股亏损为人民币2.24分，2025年同期为人民币3.03分。以上财务数据均摘自公司于同日发布的《截至2026年6月30日止六个月中期业绩公告》。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660385172","title":"泰凌医药(01011)发布中期业绩，股东应占亏损1843.3万元，同比增加9.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660385172","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660385172?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:25","pubTimestamp":1787235955,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布2026年中期业绩，该集团取得收益2366.5万元，同比增加97.29%;公司拥有人应占亏损1843.3万元，同比增加9.03%;每股亏损2.24分。目前，本集团已构建多维协同的业务矩阵：核心治疗板块以骨科创新药物“特立帕肽”的专业化分销与营销为锚点，辅以特色的骨健康中药及保健产品，形成稳固的业务基石。在此基础上，本集团通过收购人工智能骨健康诊断机器人战略性拓展诊断服务。该等智能设备利用人工智能算法实现骨密度及骨健康风险的高效精准筛查，填补本集团于骨健康早期筛查的业务空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660937774","title":"泰凌医药(01011)对裁决持有重大异议，已委聘合规法律服务团队启动申请撤销裁决等法定程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2660937774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660937774?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:47","pubTimestamp":1787064469,"startTime":"0","endTime":"0","summary":"本公司对该裁决持有重大异议，已委聘合规法律服务团队启动申请撤销裁决等法定程序。目前该裁决仍处于可依法申请撤销的法定周期内，相关付款义务尚未进入强制执行阶段。本集团日常营运及现金流目前维持正常状态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118192891","title":"泰凌医药（01011.HK）披露仲裁裁决：或承担约9,200万元人民币付款义务","url":"https://stock-news.laohu8.com/highlight/detail?id=1118192891","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118192891?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:45","pubTimestamp":1787064330,"startTime":"0","endTime":"0","summary":"泰凌医药8月18日晚间公告称，公司已于2026年7月20日收到中国国际经济贸易仲裁委员会出具的〔2026〕中國貿仲京裁字第1519號仲裁裁决。该裁决要求公司及相关连带方合计支付违约金、相关费用及仲裁分担款共计约人民币92,000,000元。仲裁源于泰凌医药于2020年与北京康辰药业股份有限公司相关主体签署的资产交易项目项下担保安排，相关股权转让已于2020年完成交割。目前该裁决仍处于法定可申请撤销期间，相关付款义务尚未进入强制执行阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139602283","title":"泰凌医药（01011）拟于8月20日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1139602283","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139602283?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:07","pubTimestamp":1786352866,"startTime":"0","endTime":"0","summary":"2026年8月10日，中国泰凌医药集团有限公司（股票代码：01011，以下简称“泰凌医药”）发布公告称，公司董事会将于2026年8月20日（星期四）举行会议。\n本次董事会会议主要议程包括：一是审批泰凌医药及其附属公司截至2026年6月30日止六个月的中期业绩；二是考虑建议派发中期股息（如有）。\n公告显示，截至公告日，公司董事会由执行董事吴铁先生、吴静美女士；非执行董事钱唯博士、钱余女士、楼勇斌先生；以及独立非执行董事余梓山先生、郭芝聪先生、赵玉彪博士组成。\n泰凌医药表示，将在董事会会议后及时发布中期业绩及相关决定的进一步信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196589577","title":"泰凌医药（01011）拟发行约8.48亿股新股以债转股　并提议更换核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1196589577","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196589577?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:46","pubTimestamp":1786351598,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司8月10日公告称，公司已于2026年6月17日分别与七名认购人签订认购协议，拟以每股0.365港元的价格发行合共847,565,892股新股份，作价合计约3.09亿港元，用以抵销公司于同日应付认购人的等额债务。上述安排及相关交易事项将提交2026年8月28日召开的股东特别大会审议。股东特别大会定于2026年8月28日11时在香港干诺道中168–200号信德中心西座21楼2102室举行。股东名册将于2026年8月25日至8月28日暂停过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147205096","title":"泰凌医药7月股份变动月报表，股本结构保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147205096","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147205096?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:36","pubTimestamp":1785933369,"startTime":"0","endTime":"0","summary":"2026年8月5日，泰凌医药公布了截至2026年7月31日的股份变动月报表。报告显示，公司本月无新增股份发行、购回及注销活动，全体已发行股份总数保持不变，股本结构整体保持稳定。公司公告披露，截至2026年7月31日，泰凌医药普通股法定/注册股本数量为62,592,500,000股，面值0.0000008美元，对应法定/注册股本50,074美元；优先股法定/注册股本数量为32,500,000股，面值同为0.0000008美元，对应法定/注册股本26美元。公司表示其公众持股量符合香港联交所相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656701583","title":"泰凌医药(01011)转仓市值总计2100.49万港元 占比5.90% 从圣衡金融控股转出5600.00万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656701583","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656701583?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:47","pubTimestamp":1785804472,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月3日，泰凌医药(01011)出现仓位异动，转仓市值总计2100.49万港元，占比5.90%。该公司股东向新永安国际证券转入5600.00万股，从圣衡金融控股转出5600.00万股。2025年度，泰凌医药取得营业收入2415.8万元人民币，同比减少36.36%；归属于上市公司股东的净亏损2604.1万元人民币，亏损同比减少51.20%；基本每股亏损0.0422元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159940","BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186451601","title":"泰凌医药（01011）披露化解“不发表意见”行动计划进展 贷款资本化可削减逾59%债务","url":"https://stock-news.laohu8.com/highlight/detail?id=1186451601","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186451601?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506784,"startTime":"0","endTime":"0","summary":"泰凌医药7月31日公告，董事会就化解截至2025年12月31日年度财报所涉“持续经营不确定性”不发表意见的行动计划公布季度最新进展，核心包括业务转型及资本结构优化两大方向。拟资本化债务占2025年12月31日集团总债务约人民币4.49亿元的59.38%。泰凌医药称，董事会将继续推进相关措施，以化解持续经营的不确定因素，并在适当时候发布进一步公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160600109","title":"泰凌医药（01011）进一步延迟寄发涉及贷款资本化事项通函","url":"https://stock-news.laohu8.com/highlight/detail?id=1160600109","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160600109?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:26","pubTimestamp":1785497210,"startTime":"0","endTime":"0","summary":"泰凌医药7月31日在港交所公告称，原定于2026年7月31日或之前寄发的有关根据特别授权认购股份以进行贷款资本化事项的通函，现需额外时间落实编制，寄发日期将进一步延迟至2026年8月14日或之前。公告回顾显示，公司曾于2026年6月17日发布涉及贷款资本化的认购协议公告，随后于2026年7月10日公告首次延迟寄发通函。公司指出，延期旨在确保通函内容的准确性与完整性，并将连同股东特别大会通告及代表委任表格一并寄发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ntpharma.com","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":0.125},{"period":"3month","weight":-0.2174},{"period":"6month","weight":-0.5068},{"period":"1year","weight":-0.6727},{"period":"ytd","weight":-0.561}],"compareEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":-0.034},{"period":"3month","weight":0.0284},{"period":"6month","weight":-0.0266},{"period":"1year","weight":-0.0856},{"period":"ytd","weight":-0.04}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国泰凌医药集团有限公司是一家主要提供医药产品销售及分销服务的投资控股公司。该公司通过两个分部运营业务。数字服务分部主要提供与骨健康知识的市场推广及宣传有关的数字服务。销售代理分部主要提供代理服务为代理客户向外部客户销售医疗及健康相关产品服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.003177},{"month":2,"riseRate":0.466667,"avgChangeRate":0.045108},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034671},{"month":4,"riseRate":0.6,"avgChangeRate":0.215361},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.031879},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.023905},{"month":7,"riseRate":0.375,"avgChangeRate":-0.017618},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.053656},{"month":9,"riseRate":0.375,"avgChangeRate":0.020824},{"month":10,"riseRate":0.4,"avgChangeRate":-0.009707},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.071764},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.020063}],"exchange":"SEHK","name":"泰凌医药","nameEN":"NT PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰凌医药,01011,泰凌医药股票,泰凌医药股票老虎,泰凌医药股票老虎国际,泰凌医药行情,泰凌医药股票行情,泰凌医药股价,泰凌医药股市,泰凌医药股票价格,泰凌医药股票交易,泰凌医药股票购买,泰凌医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}